Announced Sat, 27 Jun · 10:38 IST
US FDA inspection at Aurobindo subsidiary ends with 2 observations
Regulatory & Legal View source PDF
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.2%1-day move
₹1554.60
prior close
₹1555.20
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.7+0.8+0.6+1.8+1.2-0.3+0.5+4.0+2.6+0.2+0.3———
Up moveDown movePending
AI summary
US FDA inspected Aurobindo Pharma's wholly owned subsidiary Auroactive Pharma at its API and formulation intermediates plant in Andhra Pradesh from June 22 to June 26, 2026. The inspection ended with 2 observations, which the company will respond to within the stipulated time. The company states there is no impact on its financials or operations.
Likely market impact
Minimal near-term impact as only 2 observations and no operational disruption flagged. FDA response outcome may affect future US approvals.